- Home
- WYY vs LITS Comparison
WYY vs LITS Comparison
Compare WYY & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WYY | LITS |
|---|---|---|
| Founded | 1991 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.7M | 54.1M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | WYY | LITS |
|---|---|---|
| Price | $7.03 | $1.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | 44.9K | ★ 737.6K |
| Earning Date | 11-13-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $145,926,414.00 | N/A |
| Revenue This Year | $5.20 | N/A |
| Revenue Next Year | $15.39 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.62 | N/A |
| 52 Week Low | $2.19 | $1.30 |
| 52 Week High | $7.55 | $9.00 |
Technical Indicators
Market Signals| Indicator | WYY | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 62.15 | N/A |
| Support Level | $6.56 | N/A |
| Resistance Level | $7.26 | N/A |
| Average True Range (ATR) | 0.39 | 0.00 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 88.06 | 0.00 |
Price Performance
Historical ComparisonAbout WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.